

Katerina Zavitsanou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8055391/publications.pdf>

Version: 2024-02-01

34
papers

1,350
citations

394421

19
h-index

414414

32
g-index

36
all docs

36
docs citations

36
times ranked

1601
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Immune Activation during Early or Late Gestation on N-Methyl-d-Aspartate Receptor Measures in Adult Rat Offspring. <i>Frontiers in Psychiatry</i> , 2017, 8, 77.	2.6	34
2	Alteration of transcriptional networks in the entorhinal cortex after maternal immune activation and adolescent cannabinoid exposure. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 187-196.	4.1	24
3	Testosterone attenuates and the selective estrogen receptor modulator, raloxifene, potentiates amphetamine-induced locomotion in male rats. <i>Hormones and Behavior</i> , 2015, 70, 73-84.	2.1	14
4	ISDN2014_0222: Adolescent cannabinoid exposure after maternal immune activation increases proliferation in the adult subventricular zone. <i>International Journal of Developmental Neuroscience</i> , 2015, 47, 67-67.	1.6	0
5	Mismatch Negativity (MMN) in Freely-Moving Rats with Several Experimental Controls. <i>PLoS ONE</i> , 2014, 9, e110892.	2.5	70
6	Prenatal poly I:C age-dependently alters cannabinoid type 1 receptors in offspring: A longitudinal small animal PET study using [¹⁸ F]MK-9470. <i>Experimental Neurology</i> , 2014, 257, 162-169.	4.1	17
7	Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition. <i>Brain, Behavior, and Immunity</i> , 2014, 41, 173-181.	4.1	35
8	Neonatal lipopolysaccharide treatment has long-term effects on monoaminergic and cannabinoid receptors in the rat. <i>Synapse</i> , 2013, 67, 290-299.	1.2	25
9	Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT _{1A} Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia. , 2012, 2012, 1-9.		37
10	Differential Treatment Regimen-Related Effects of HU210 on CB ₁ and D ₂ -Like Receptor Functionality in the Rat Basal Ganglia. <i>Pharmacology</i> , 2012, 89, 64-73.	2.2	2
11	Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: Exploration of drug targets through the Stanley Neuropathology Integrative Database. <i>European Neuropsychopharmacology</i> , 2012, 22, 683-694.	0.7	16
12	Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: A small animal PET imaging study with ¹⁸ F-FDG. <i>Brain Research Bulletin</i> , 2012, 87, 172-179.	3.0	14
13	Paranoid Schizophrenia is Characterized by Increased CB ₁ Receptor Binding in the Dorsolateral Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2011, 36, 1620-1630.	5.4	99
14	Comparison of Cannabinoid CB ₁ Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [¹⁸ F]MK-9470. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-11.	1.3	34
15	Rapid Changes in D1 and D2 Dopamine Receptor Binding in Striatal Subregions after a Single Dose of Phencyclidine. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 67-72.	2.0	6
16	GABAA receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. <i>Brain Research</i> , 2010, 1351, 238-245.	2.2	17
17	Cannabinoid effects on CB ₁ receptor density in the adolescent brain: An autoradiographic study using the synthetic cannabinoid HU210. <i>Synapse</i> , 2010, 64, 845-854.	1.2	43
18	ADOLESCENT RATS SHOW A REDUCED NEUROCHEMICAL REACTION COMPARED TO ADULTS IN RESPONSE TO CANNABINOID ADMINISTRATION. <i>Schizophrenia Research</i> , 2010, 117, 388.	2.0	0

#	ARTICLE	IF	CITATIONS
19	Receptor changes in brain tissue of rats treated as neonates with capsaicin. Journal of Chemical Neuroanatomy, 2010, 39, 248-255.	2.1	12
20	Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain. Journal of Chemical Neuroanatomy, 2010, 40, 272-280.	2.1	16
21	HU210-Induced Downregulation in Cannabinoid CB1 Receptor Binding Strongly Correlates with Body Weight Loss in the Adult Rat. Neurochemical Research, 2009, 34, 1343-1353.	3.3	28
22	Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research, 2008, 86, 457-464.	2.9	25
23	Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia. Journal of Chemical Neuroanatomy, 2008, 36, 71-76.	2.1	14
24	Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 225-233.	4.8	79
25	Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. Journal of Neuroscience Research, 2007, 85, 1358-1363.	2.9	10
26	Effects of Typical and Atypical Antipsychotic Drugs on Rat Brain Muscarinic Receptors. Neurochemical Research, 2007, 32, 525-532.	3.3	11
27	Olanzapine differentially affects 5-HT _{2A} and 2C receptor mRNA expression in the rat brain. Behavioural Brain Research, 2006, 171, 355-362.	2.2	63
28	Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides, 2006, 40, 213-219.	2.2	42
29	Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. NeuroReport, 2005, 16, 1363-1367.	1.2	34
30	M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Research Bulletin, 2005, 65, 397-403.	3.0	49
31	Investigation of M1/M4 Muscarinic Receptors in the Anterior Cingulate Cortex in Schizophrenia, Bipolar Disorder, and Major Depression Disorder. Neuropsychopharmacology, 2004, 29, 619-625.	5.4	143
32	Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 355-360.	4.8	236
33	M1 Receptor Agonism, a Possible Treatment for Cognitive Deficits in Schizophrenia. Neuropsychopharmacology, 2004, 29, 1585-1586.	5.4	32
34	Selective Alterations in Ionotropic Glutamate Receptors in the Anterior Cingulate Cortex in Schizophrenia. Neuropsychopharmacology, 2002, 27, 826-833.	5.4	66